<DOC>
	<DOCNO>NCT00410657</DOCNO>
	<brief_summary>RATIONALE : Alemtuzumab glucocorticoid , prednisone methylprednisolone , may effective treatment acute graft-versus-host disease cause donor stem cell transplant . PURPOSE : This phase II trial study well give alemtuzumab together glucocorticoid work treat newly diagnose acute graft-versus-host disease patient undergone donor stem cell transplant .</brief_summary>
	<brief_title>Alemtuzumab Glucocorticoids Treating Newly Diagnosed Acute Graft-Versus-Host Disease Patients Who Have Undergone Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether administration low-dose alemtuzumab onset acute graft-versus-host disease accelerate withdrawal glucocorticoid decrease nonrelapsing mortality patient undergone myeloablative allogeneic stem cell transplantation . OUTLINE : This open-label , nonrandomized study . Within 72 hour begin glucocorticoid therapy , patient receive alemtuzumab IV least 2 hour day 1 2 . If graft-versus-host disease ( GVHD ) respond well day 1-14 return day 28 56 , patient eligible receive 2 additional dos alemtuzumab . Patients receive glucocorticoid therapy comprise methylprednisolone IV oral prednisone daily objective evidence improvement manifestation GVHD . Patients resolve significantly improve GVHD receive treatment day 10 follow accelerated taper day 72 flare GVHD occur glucocorticoid taper . Patients recurrent progressive GVHD accelerate taper treated 5-7 day resume less rapid taper . Patients improvement may receive secondary therapy alternative immunosuppressive medication discretion manage physician . Treatment continue absence progressive GVHD least 3 day duration day 2-10 ; persist GVHD without improvement day 10-14 ; recurrent progressive GVHD day 10 respond within 3 day topical immunosuppressive therapy ; and/or increase systemic glucocorticoid dose two taper step ; unacceptable toxicity . Patients undergo blood collection baseline periodically study treatment pharmacokinetics quantification viral load human herpes virus 6 , adenovirus , Epstein-Barr virus , cytomegalovirus . Samples also examine flow cytometry B- T-cell quantification baseline , periodically study treatment , 1 year transplantation . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 53 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Trophoblastic Neoplasms</mesh_term>
	<mesh_term>Gestational Trophoblastic Disease</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute graftversushost disease ( GVHD ) Grade IIBIV disease Requires glucocorticoids treatment GVHD , indicate 1 following : Initial treatment prednisone methylprednisolone 2 mg/kg indicate ( judgement attend physician ) following : Severity GVHD require hospitalization GVHD manifestation include symptom anorexia , nausea , vomit GVHD begin within 23 week hematopoietic stem cell transplantation ( HSCT ) GVHD manifestation progress rapidly 1 day next treatment Initial treatment prednisone methylprednisolone 1 mg/kg produce adequate clinical improvement within first 4 day ( judgement attend physician ) Has undergone allogeneic HSCT myeloablative conditioning No nonmyeloablative conditioning autologous HSCT No primary treatment acute GVHD methylprednisolone follow dos : More 2 mg/kg/day time 2 mg/kg/day &gt; 72 hour 1 mg/kg/day &gt; 96 hour No presence distinctive diagnostic manifestation chronic GVHD No relapse , refractory , secondary malignancy PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 20100 % OR Lanksy PS 20100 % Life expectancy ≥ 1 month Absolute neutrophil count ≥ 500/mm^3 Negative pregnancy test No Mini Mental State Exam score &lt; 24/30 confusion ( patient &gt; 12 year age ) No history type I hypersensitivity reaction alemtuzumab components No increase level viremia serial quantitative viral plasma polymerase chain reaction assay No invasive viral fungal disease respond appropriate antiviral antifungal medication PRIOR CONCURRENT THERAPY : See Disease Characteristics No systemic immunosuppression taper stop treatment leukemic relapse minimal residual disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>poor prognosis metastatic gestational trophoblastic tumor</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>aggressive , noncontiguous stage II adult non-Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>